Feasibility of quantifying SDC2 methylation in stool DNA for early detection of colorectal cancer

Background Colorectal cancer (CRC) screening is the most efficient strategy to reduce disease-related mortality. Frequent aberrant DNA methylation is known to occur in selected genes and early during CRC development, which has emerged as a new epigenetic biomarker for early detection of CRC. Previou...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical epigenetics Vol. 9; no. 1; pp. 126 - 11
Main Authors:	Oh, Tae Jeong, Oh, Hyun Il, Seo, Yang Yei, Jeong, Dongjun, Kim, Changjin, Kang, Hyoun Woo, Han, Yoon Dae, Chung, Hyun Cheol, Kim, Nam Kyu, An, Sungwhan
Format:	Journal Article
Language:	English
Published:	London BioMed Central 04.12.2017 BioMed Central Ltd BMC
Subjects:	Adult Aged Analysis Biomarkers, Tumor - genetics Biomedical and Life Sciences Biomedicine Cancer epigenetics and diagnostics Cancer screening Colorectal cancer Colorectal Neoplasms - diagnosis Colorectal Neoplasms - genetics CpG Islands Development and progression DNA Methylation Early detection Epigenesis, Genetic Feasibility Studies Feces - chemistry Female Gene Function HCT116 Cells Health aspects HT29 Cells Human Genetics Humans Male Methylation Middle Aged Mortality Precancerous lesion SDC2 Sensitivity and Specificity Sequence Analysis, DNA Stool DNA Syndecan-2 - genetics Methylation Stool DNA Precancerous lesion Early detection Colorectal cancer SDC2
ISSN:	1868-7075, 1868-7083, 1868-7083
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Background Colorectal cancer (CRC) screening is the most efficient strategy to reduce disease-related mortality. Frequent aberrant DNA methylation is known to occur in selected genes and early during CRC development, which has emerged as a new epigenetic biomarker for early detection of CRC. Previously, we reported that we identified that CpG sites of SDC2 were aberrantly methylated in tumor tissues of most CRC patients through comprehensive methylation analysis and demonstrated a high potential of quantification of SDC2 methylation in blood for early detection of colorectal cancer. In this study, we aim to investigate the feasibility of quantifying SDC2 methylation in stool DNA for the early detection of CRC. The objective of this study was to confirm a high frequency of SDC2 methylation in tumor tissues at various stages of CRC and investigate the feasibility of a quantitative test for SDC2 methylation in fecal DNA by highly sensitive and accurate real-time PCR for early detection of CRC. Methods Bisulfite-pyrosequencing assay was performed to measure the SDC2 methylation status in tissue samples. For methylation analysis in stool DNA, a highly sensitive and accurate method was applied which implements consecutive two rounds of PCR consisting of unidirectional linear target enrichment (LTE) of SDC2 and quantitative methylation-specific real time PCR (qMSP) for SDC2 , named as me SDC2 LTE-qMSP assay. Its limit of detection was 0.1% methylation (corresponding to ~ 6 copies in total ~ 6200 genome copies). Results Positive SDC2 methylation was observed in 100% of primary tumors, 90.6% of adenomatous polyps, 94.1% of hyperplastic polyps, and 0% of normal tissues. SDC2 methylation level also significantly ( P < 0.01) increased according to the severity of lesions. In stool DNA test for SDC2 methylation by LTE-qMSP comparing CRC patients with various stages (I to IV) ( n = 50) and precancerous lesions ( n = 21) with healthy subjects ( n = 22), the overall sensitivity was 90.0% for detecting CRC and 33.3% for detecting small polyps, with a specificity of 90.9%. Conclusions Taken together, our result indicates that stool DNA-based SDC2 methylation test by LTE-qMSP is a potential noninvasive diagnostic tool for early detection of CRC.
AbstractList	Colorectal cancer (CRC) screening is the most efficient strategy to reduce disease-related mortality. Frequent aberrant DNA methylation is known to occur in selected genes and early during CRC development, which has emerged as a new epigenetic biomarker for early detection of CRC. Previously, we reported that we identified that CpG sites of SDC2 were aberrantly methylated in tumor tissues of most CRC patients through comprehensive methylation analysis and demonstrated a high potential of quantification of SDC2 methylation in blood for early detection of colorectal cancer. In this study, we aim to investigate the feasibility of quantifying SDC2 methylation in stool DNA for the early detection of CRC. The objective of this study was to confirm a high frequency of SDC2 methylation in tumor tissues at various stages of CRC and investigate the feasibility of a quantitative test for SDC2 methylation in fecal DNA by highly sensitive and accurate real-time PCR for early detection of CRC. Bisulfite-pyrosequencing assay was performed to measure the SDC2 methylation status in tissue samples. For methylation analysis in stool DNA, a highly sensitive and accurate method was applied which implements consecutive two rounds of PCR consisting of unidirectional linear target enrichment (LTE) of SDC2 and quantitative methylation-specific real time PCR (qMSP) for SDC2, named as meSDC2 LTE-qMSP assay. Its limit of detection was 0.1% methylation (corresponding to ~ 6 copies in total ~ 6200 genome copies). Positive SDC2 methylation was observed in 100% of primary tumors, 90.6% of adenomatous polyps, 94.1% of hyperplastic polyps, and 0% of normal tissues. SDC2 methylation level also significantly (P < 0.01) increased according to the severity of lesions. In stool DNA test for SDC2 methylation by LTE-qMSP comparing CRC patients with various stages (I to IV) (n = 50) and precancerous lesions (n = 21) with healthy subjects (n = 22), the overall sensitivity was 90.0% for detecting CRC and 33.3% for detecting small polyps, with a specificity of 90.9%. Taken together, our result indicates that stool DNA-based SDC2 methylation test by LTE-qMSP is a potential noninvasive diagnostic tool for early detection of CRC. Colorectal cancer (CRC) screening is the most efficient strategy to reduce disease-related mortality. Frequent aberrant DNA methylation is known to occur in selected genes and early during CRC development, which has emerged as a new epigenetic biomarker for early detection of CRC. Previously, we reported that we identified that CpG sites of SDC2 were aberrantly methylated in tumor tissues of most CRC patients through comprehensive methylation analysis and demonstrated a high potential of quantification of SDC2 methylation in blood for early detection of colorectal cancer. In this study, we aim to investigate the feasibility of quantifying SDC2 methylation in stool DNA for the early detection of CRC. The objective of this study was to confirm a high frequency of SDC2 methylation in tumor tissues at various stages of CRC and investigate the feasibility of a quantitative test for SDC2 methylation in fecal DNA by highly sensitive and accurate real-time PCR for early detection of CRC.BACKGROUNDColorectal cancer (CRC) screening is the most efficient strategy to reduce disease-related mortality. Frequent aberrant DNA methylation is known to occur in selected genes and early during CRC development, which has emerged as a new epigenetic biomarker for early detection of CRC. Previously, we reported that we identified that CpG sites of SDC2 were aberrantly methylated in tumor tissues of most CRC patients through comprehensive methylation analysis and demonstrated a high potential of quantification of SDC2 methylation in blood for early detection of colorectal cancer. In this study, we aim to investigate the feasibility of quantifying SDC2 methylation in stool DNA for the early detection of CRC. The objective of this study was to confirm a high frequency of SDC2 methylation in tumor tissues at various stages of CRC and investigate the feasibility of a quantitative test for SDC2 methylation in fecal DNA by highly sensitive and accurate real-time PCR for early detection of CRC.Bisulfite-pyrosequencing assay was performed to measure the SDC2 methylation status in tissue samples. For methylation analysis in stool DNA, a highly sensitive and accurate method was applied which implements consecutive two rounds of PCR consisting of unidirectional linear target enrichment (LTE) of SDC2 and quantitative methylation-specific real time PCR (qMSP) for SDC2, named as meSDC2 LTE-qMSP assay. Its limit of detection was 0.1% methylation (corresponding to ~ 6 copies in total ~ 6200 genome copies).METHODSBisulfite-pyrosequencing assay was performed to measure the SDC2 methylation status in tissue samples. For methylation analysis in stool DNA, a highly sensitive and accurate method was applied which implements consecutive two rounds of PCR consisting of unidirectional linear target enrichment (LTE) of SDC2 and quantitative methylation-specific real time PCR (qMSP) for SDC2, named as meSDC2 LTE-qMSP assay. Its limit of detection was 0.1% methylation (corresponding to ~ 6 copies in total ~ 6200 genome copies).Positive SDC2 methylation was observed in 100% of primary tumors, 90.6% of adenomatous polyps, 94.1% of hyperplastic polyps, and 0% of normal tissues. SDC2 methylation level also significantly (P < 0.01) increased according to the severity of lesions. In stool DNA test for SDC2 methylation by LTE-qMSP comparing CRC patients with various stages (I to IV) (n = 50) and precancerous lesions (n = 21) with healthy subjects (n = 22), the overall sensitivity was 90.0% for detecting CRC and 33.3% for detecting small polyps, with a specificity of 90.9%.RESULTSPositive SDC2 methylation was observed in 100% of primary tumors, 90.6% of adenomatous polyps, 94.1% of hyperplastic polyps, and 0% of normal tissues. SDC2 methylation level also significantly (P < 0.01) increased according to the severity of lesions. In stool DNA test for SDC2 methylation by LTE-qMSP comparing CRC patients with various stages (I to IV) (n = 50) and precancerous lesions (n = 21) with healthy subjects (n = 22), the overall sensitivity was 90.0% for detecting CRC and 33.3% for detecting small polyps, with a specificity of 90.9%.Taken together, our result indicates that stool DNA-based SDC2 methylation test by LTE-qMSP is a potential noninvasive diagnostic tool for early detection of CRC.CONCLUSIONSTaken together, our result indicates that stool DNA-based SDC2 methylation test by LTE-qMSP is a potential noninvasive diagnostic tool for early detection of CRC. Colorectal cancer (CRC) screening is the most efficient strategy to reduce disease-related mortality. Frequent aberrant DNA methylation is known to occur in selected genes and early during CRC development, which has emerged as a new epigenetic biomarker for early detection of CRC. Previously, we reported that we identified that CpG sites of were aberrantly methylated in tumor tissues of most CRC patients through comprehensive methylation analysis and demonstrated a high potential of quantification of methylation in blood for early detection of colorectal cancer. In this study, we aim to investigate the feasibility of quantifying methylation in stool DNA for the early detection of CRC. The objective of this study was to confirm a high frequency of methylation in tumor tissues at various stages of CRC and investigate the feasibility of a quantitative test for methylation in fecal DNA by highly sensitive and accurate real-time PCR for early detection of CRC. Bisulfite-pyrosequencing assay was performed to measure the methylation status in tissue samples. For methylation analysis in stool DNA, a highly sensitive and accurate method was applied which implements consecutive two rounds of PCR consisting of unidirectional linear target enrichment (LTE) of and quantitative methylation-specific real time PCR (qMSP) for , named as me LTE-qMSP assay. Its limit of detection was 0.1% methylation (corresponding to ~ 6 copies in total ~ 6200 genome copies). Positive methylation was observed in 100% of primary tumors, 90.6% of adenomatous polyps, 94.1% of hyperplastic polyps, and 0% of normal tissues. methylation level also significantly ( < 0.01) increased according to the severity of lesions. In stool DNA test for methylation by LTE-qMSP comparing CRC patients with various stages (I to IV) ( = 50) and precancerous lesions ( = 21) with healthy subjects ( = 22), the overall sensitivity was 90.0% for detecting CRC and 33.3% for detecting small polyps, with a specificity of 90.9%. Taken together, our result indicates that stool DNA-based methylation test by LTE-qMSP is a potential noninvasive diagnostic tool for early detection of CRC. Background Colorectal cancer (CRC) screening is the most efficient strategy to reduce disease-related mortality. Frequent aberrant DNA methylation is known to occur in selected genes and early during CRC development, which has emerged as a new epigenetic biomarker for early detection of CRC. Previously, we reported that we identified that CpG sites of SDC2 were aberrantly methylated in tumor tissues of most CRC patients through comprehensive methylation analysis and demonstrated a high potential of quantification of SDC2 methylation in blood for early detection of colorectal cancer. In this study, we aim to investigate the feasibility of quantifying SDC2 methylation in stool DNA for the early detection of CRC. The objective of this study was to confirm a high frequency of SDC2 methylation in tumor tissues at various stages of CRC and investigate the feasibility of a quantitative test for SDC2 methylation in fecal DNA by highly sensitive and accurate real-time PCR for early detection of CRC. Methods Bisulfite-pyrosequencing assay was performed to measure the SDC2 methylation status in tissue samples. For methylation analysis in stool DNA, a highly sensitive and accurate method was applied which implements consecutive two rounds of PCR consisting of unidirectional linear target enrichment (LTE) of SDC2 and quantitative methylation-specific real time PCR (qMSP) for SDC2 , named as me SDC2 LTE-qMSP assay. Its limit of detection was 0.1% methylation (corresponding to ~ 6 copies in total ~ 6200 genome copies). Results Positive SDC2 methylation was observed in 100% of primary tumors, 90.6% of adenomatous polyps, 94.1% of hyperplastic polyps, and 0% of normal tissues. SDC2 methylation level also significantly ( P < 0.01) increased according to the severity of lesions. In stool DNA test for SDC2 methylation by LTE-qMSP comparing CRC patients with various stages (I to IV) ( n = 50) and precancerous lesions ( n = 21) with healthy subjects ( n = 22), the overall sensitivity was 90.0% for detecting CRC and 33.3% for detecting small polyps, with a specificity of 90.9%. Conclusions Taken together, our result indicates that stool DNA-based SDC2 methylation test by LTE-qMSP is a potential noninvasive diagnostic tool for early detection of CRC. Background Colorectal cancer (CRC) screening is the most efficient strategy to reduce disease-related mortality. Frequent aberrant DNA methylation is known to occur in selected genes and early during CRC development, which has emerged as a new epigenetic biomarker for early detection of CRC. Previously, we reported that we identified that CpG sites of SDC2 were aberrantly methylated in tumor tissues of most CRC patients through comprehensive methylation analysis and demonstrated a high potential of quantification of SDC2 methylation in blood for early detection of colorectal cancer. In this study, we aim to investigate the feasibility of quantifying SDC2 methylation in stool DNA for the early detection of CRC. The objective of this study was to confirm a high frequency of SDC2 methylation in tumor tissues at various stages of CRC and investigate the feasibility of a quantitative test for SDC2 methylation in fecal DNA by highly sensitive and accurate real-time PCR for early detection of CRC. Methods Bisulfite-pyrosequencing assay was performed to measure the SDC2 methylation status in tissue samples. For methylation analysis in stool DNA, a highly sensitive and accurate method was applied which implements consecutive two rounds of PCR consisting of unidirectional linear target enrichment (LTE) of SDC2 and quantitative methylation-specific real time PCR (qMSP) for SDC2, named as meSDC2 LTE-qMSP assay. Its limit of detection was 0.1% methylation (corresponding to ~ 6 copies in total ~ 6200 genome copies). Results Positive SDC2 methylation was observed in 100% of primary tumors, 90.6% of adenomatous polyps, 94.1% of hyperplastic polyps, and 0% of normal tissues. SDC2 methylation level also significantly (P < 0.01) increased according to the severity of lesions. In stool DNA test for SDC2 methylation by LTE-qMSP comparing CRC patients with various stages (I to IV) (n = 50) and precancerous lesions (n = 21) with healthy subjects (n = 22), the overall sensitivity was 90.0% for detecting CRC and 33.3% for detecting small polyps, with a specificity of 90.9%. Conclusions Taken together, our result indicates that stool DNA-based SDC2 methylation test by LTE-qMSP is a potential noninvasive diagnostic tool for early detection of CRC. Keywords: Colorectal cancer, Early detection, Methylation, Precancerous lesion, SDC2, Stool DNA Abstract Background Colorectal cancer (CRC) screening is the most efficient strategy to reduce disease-related mortality. Frequent aberrant DNA methylation is known to occur in selected genes and early during CRC development, which has emerged as a new epigenetic biomarker for early detection of CRC. Previously, we reported that we identified that CpG sites of SDC2 were aberrantly methylated in tumor tissues of most CRC patients through comprehensive methylation analysis and demonstrated a high potential of quantification of SDC2 methylation in blood for early detection of colorectal cancer. In this study, we aim to investigate the feasibility of quantifying SDC2 methylation in stool DNA for the early detection of CRC. The objective of this study was to confirm a high frequency of SDC2 methylation in tumor tissues at various stages of CRC and investigate the feasibility of a quantitative test for SDC2 methylation in fecal DNA by highly sensitive and accurate real-time PCR for early detection of CRC. Methods Bisulfite-pyrosequencing assay was performed to measure the SDC2 methylation status in tissue samples. For methylation analysis in stool DNA, a highly sensitive and accurate method was applied which implements consecutive two rounds of PCR consisting of unidirectional linear target enrichment (LTE) of SDC2 and quantitative methylation-specific real time PCR (qMSP) for SDC2, named as meSDC2 LTE-qMSP assay. Its limit of detection was 0.1% methylation (corresponding to ~ 6 copies in total ~ 6200 genome copies). Results Positive SDC2 methylation was observed in 100% of primary tumors, 90.6% of adenomatous polyps, 94.1% of hyperplastic polyps, and 0% of normal tissues. SDC2 methylation level also significantly (P < 0.01) increased according to the severity of lesions. In stool DNA test for SDC2 methylation by LTE-qMSP comparing CRC patients with various stages (I to IV) (n = 50) and precancerous lesions (n = 21) with healthy subjects (n = 22), the overall sensitivity was 90.0% for detecting CRC and 33.3% for detecting small polyps, with a specificity of 90.9%. Conclusions Taken together, our result indicates that stool DNA-based SDC2 methylation test by LTE-qMSP is a potential noninvasive diagnostic tool for early detection of CRC.
ArticleNumber	126
Audience	Academic
Author	Jeong, Dongjun Kang, Hyoun Woo Chung, Hyun Cheol Seo, Yang Yei Kim, Changjin An, Sungwhan Oh, Tae Jeong Han, Yoon Dae Oh, Hyun Il Kim, Nam Kyu
Author_xml	– sequence: 1 givenname: Tae Jeong surname: Oh fullname: Oh, Tae Jeong organization: Genomictree, Inc – sequence: 2 givenname: Hyun Il surname: Oh fullname: Oh, Hyun Il organization: Genomictree, Inc – sequence: 3 givenname: Yang Yei surname: Seo fullname: Seo, Yang Yei organization: Genomictree, Inc – sequence: 4 givenname: Dongjun surname: Jeong fullname: Jeong, Dongjun organization: Department of Pathology, College of Medicine, Soonchunhyang University – sequence: 5 givenname: Changjin surname: Kim fullname: Kim, Changjin organization: Department of Pathology, College of Medicine, Soonchunhyang University – sequence: 6 givenname: Hyoun Woo surname: Kang fullname: Kang, Hyoun Woo organization: Department of Internal Medicine, Dongguk University Ilsan Hospital, College of Medicine, Dongguk University – sequence: 7 givenname: Yoon Dae surname: Han fullname: Han, Yoon Dae organization: Department of Surgery, Yonsei University College of Medicine – sequence: 8 givenname: Hyun Cheol surname: Chung fullname: Chung, Hyun Cheol organization: Yonsei Cancer Center Yonsei University College of Medicine – sequence: 9 givenname: Nam Kyu surname: Kim fullname: Kim, Nam Kyu organization: Department of Surgery, Yonsei University College of Medicine – sequence: 10 givenname: Sungwhan orcidid: 0000-0001-8781-4186 surname: An fullname: An, Sungwhan email: genomictree1@korea.com organization: Genomictree, Inc
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/29225717$$D View this record in MEDLINE/PubMed
BookMark	eNp9kkFv2yAYhq2p09p1_QG7TJZ22cUd2BjwZVKUrlulajtsOyMMHy4RgRZIpfz7kbiLlmkqPoA_nvf1h3lfVyc-eKiqtxhdYszpx4Q7THiDMGsQaWnTvajOSp03DPHu5LBm_Wl1kdIKldENw4DRq-q0Hdq2Z5idVfIaZLKjdTZv62Dqh4302Zqt9VP942rZ1mvId1snsw2-tr5OOQRXX31b1CbEGmR021pDBrUHioEKLsTyKl2tpFcQ31QvjXQJLp7m8-rX9eefy6_N7fcvN8vFbaMowbnp1QhoZLKciZKRQjfIvkOdpsCBGk17TTSnSBqsMJJUG2KMRqOWlGvgfOzOq5vZVwe5EvfRrmXciiCt2BdCnISM2SoHQmPSMQJ85IiSdgCJFIZO8nYcDaMUF69Ps9f9ZlyDVuBzlO7I9HjH2zsxhUdRfmpPW1oMPjwZxPCwgZTF2iYFzkkPYZMEHljfD6wlqKDvZ3SSpTXrTSiOaoeLRY8Z4aQlpFCX_6HKo2FtVUmGsaV-JHj39xEOvf-5-gLgGVAxpBTBHBCMxC5hYk6YKAkTu4SJrmjYPxpl8z4bpRvrnlW2szKVr_gJoliFTfQlEM-IfgO2EuQv
CitedBy_id	crossref_primary_10_1007_s00384_022_04170_2 crossref_primary_10_1186_s13148_019_0642_0 crossref_primary_10_1186_s13148_023_01443_7 crossref_primary_10_1002_advs_202401137 crossref_primary_10_1016_j_jmoldx_2023_05_003 crossref_primary_10_1186_s12876_022_02512_6 crossref_primary_10_1186_s13148_020_00954_x crossref_primary_10_3892_ol_2022_13600 crossref_primary_10_1016_j_clinbiochem_2024_110717 crossref_primary_10_3390_cancers14030817 crossref_primary_10_1038_s41598_025_95712_5 crossref_primary_10_1186_s12935_021_01935_7 crossref_primary_10_1016_j_compbiomed_2023_107884 crossref_primary_10_1186_s12876_021_01759_9 crossref_primary_10_3389_fmolb_2021_706754 crossref_primary_10_4103_jcrt_jcrt_1072_22 crossref_primary_10_3390_ijms22179185 crossref_primary_10_1007_s00432_023_04943_4 crossref_primary_10_1002_2211_5463_13180 crossref_primary_10_1016_j_isci_2024_111177 crossref_primary_10_1186_s12885_024_12990_4 crossref_primary_10_2147_CMAR_S300861 crossref_primary_10_1515_cclm_2022_0206 crossref_primary_10_1021_prechem_5c00014 crossref_primary_10_1093_gastro_goaf029 crossref_primary_10_3389_fonc_2025_1562698 crossref_primary_10_1186_s13148_020_00904_7 crossref_primary_10_4103_sjg_sjg_228_22 crossref_primary_10_1002_cam4_6511 crossref_primary_10_3390_life15030482 crossref_primary_10_1002_cam4_2475 crossref_primary_10_3389_fonc_2023_1166796 crossref_primary_10_1186_s12876_022_02470_z crossref_primary_10_1186_s13148_023_01555_0 crossref_primary_10_1097_MD_0000000000025909 crossref_primary_10_1186_s12967_025_06495_2 crossref_primary_10_1007_s12253_018_0505_6 crossref_primary_10_3390_cancers13194965 crossref_primary_10_3389_fgene_2019_00621 crossref_primary_10_1111_codi_15521 crossref_primary_10_1007_s00384_024_04713_9 crossref_primary_10_1155_2019_5232780 crossref_primary_10_14309_ctg_0000000000000386 crossref_primary_10_1186_s12876_022_02175_3 crossref_primary_10_1515_cclm_2020_0300 crossref_primary_10_1155_2022_9940566 crossref_primary_10_12677_acm_2025_1551676 crossref_primary_10_3389_fgene_2020_00324 crossref_primary_10_3389_fgene_2020_00643 crossref_primary_10_4240_wjgs_v15_i9_2032 crossref_primary_10_2217_epi_2023_0290 crossref_primary_10_4251_wjgo_v12_i1_1 crossref_primary_10_12998_wjcc_v7_i19_2916 crossref_primary_10_1186_s12876_022_02395_7 crossref_primary_10_1007_s12029_023_00990_9 crossref_primary_10_1155_2020_8816070 crossref_primary_10_3389_fendo_2020_00467 crossref_primary_10_3390_biology13010015 crossref_primary_10_3389_fonc_2021_647066 crossref_primary_10_1016_j_jmoldx_2021_10_012 crossref_primary_10_1177_1724600818820536 crossref_primary_10_1155_2021_6613987 crossref_primary_10_3892_or_2021_8128 crossref_primary_10_2147_JMDH_S465286 crossref_primary_10_3748_wjg_v30_i46_4950 crossref_primary_10_1016_j_cca_2020_01_010 crossref_primary_10_1007_s00432_019_02992_2 crossref_primary_10_1186_s12876_022_02264_3 crossref_primary_10_4251_wjgo_v16_i4_1119 crossref_primary_10_14309_ajg_0000000000003044
Cites_doi	10.3748/wjg.v20.i20.6329 10.3389/fpubh.2014.00210 10.1158/1055-9965.EPI-05-0992 10.1016/S1542-3565(04)00624-X 10.1083/jcb.149.5.995 10.1016/j.jmoldx.2013.03.004 10.1158/1078-0432.CCR-06-2531 10.1074/jbc.M109.054254 10.1158/1541-7786.MCR-06-0034 10.1053/j.gastro.2011.10.031 10.1186/1471-2199-8-91 10.1373/clinchem.2008.122937 10.1097/MIB.0000000000000795 10.1093/nar/gkn113 10.1016/S0140-6736(04)16002-9 10.1158/0008-5472.CAN-08-0142 10.1038/onc.2009.122 10.1177/0194599813490895 10.3390/genes7120125 10.1016/S1525-1578(10)60536-3 10.3892/or.2014.3149 10.1056/NEJM200007203430301 10.1158/1055-9965 10.3322/caac.20006 10.1093/jnci/dji204 10.1016/S0046-8177(00)80198-7 10.3748/wjg.v21.i35.10057 10.1038/ajg.2009.104 10.1056/NEJMoa1311194 10.2353/jmoldx.2007.060209 10.1016/j.gastro.2005.05.056 10.1158/0008-5472.CAN-04-2438 10.1038/nrc1045 10.1016/S0065-230X(08)60702-2 10.1186/s12896-015-0148-6 10.3748/wjg.14.524 10.3748/wjg.v13.i6.950
ContentType	Journal Article
Copyright	The Author(s). 2017 COPYRIGHT 2017 BioMed Central Ltd.
Copyright_xml	– notice: The Author(s). 2017 – notice: COPYRIGHT 2017 BioMed Central Ltd.
DBID	C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA
DOI	10.1186/s13148-017-0426-3
DatabaseName	Springer Nature OA Free Journals (WRLC) CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Zoology
EISSN	1868-7083
EndPage	11
ExternalDocumentID	oai_doaj_org_article_d14374e8b806429ea0c1e3a82bbf7661 PMC5715626 A517484244 29225717 10_1186_s13148_017_0426_3
Genre	Journal Article
GrantInformation_xml	– fundername: Ministry of SMEs and Startups (Project No. S2127072), South Korea. – fundername: ;
GroupedDBID	--- 0R~ 2JY 4.4 53G 5C9 5VS 7X7 88E 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AASML ABDBF ABUWG ACGFS ACUHS ADBBV ADRAZ ADUKV AENEX AFKRA AFPKN AHBYD AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS BAPOH BAWUL BBNVY BCNDV BENPR BFQNJ BHPHI BMC BPHCQ BVXVI C6C CCPQU DIK EBLON EBS EJD EN4 F5P FYUFA GROUPED_DOAJ GX1 H13 HCIFZ HF~ HMCUK HYE HZ~ IAO IHR INH INR ITC KOV KQ8 LK8 M1P M48 M7P O9I OK1 PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO QOS R9I RBZ RNS ROL RPM RSV S27 SBL SOJ T13 U2A UKHRP WK8 AAYXX AFFHD CITATION -A0 2VQ 3V. AAYZH ACRMQ ADINQ AGJBK AHSBF ALIPV C24 CGR CUY CVF ECM EIF IPNFZ M~E NPM O9- RIG S1Z 7X8 5PM
ID	FETCH-LOGICAL-c641t-5cbe0b7a14864b6e39a5303d6e8e6fd65d4d860af1c10a6df4ffd0bda68de88b3
IEDL.DBID	DOA
ISICitedReferencesCount	85
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000416971800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1868-7075 1868-7083
IngestDate	Tue Oct 14 19:06:12 EDT 2025 Tue Nov 04 01:57:41 EST 2025 Thu Oct 02 11:58:02 EDT 2025 Tue Nov 11 10:31:44 EST 2025 Tue Nov 04 17:58:23 EST 2025 Thu Jan 02 22:55:02 EST 2025 Sat Nov 29 06:11:47 EST 2025 Tue Nov 18 22:34:09 EST 2025 Sat Sep 06 07:30:45 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	Methylation Stool DNA Precancerous lesion Early detection Colorectal cancer SDC2
Language	English
License	Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c641t-5cbe0b7a14864b6e39a5303d6e8e6fd65d4d860af1c10a6df4ffd0bda68de88b3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ORCID	0000-0001-8781-4186
OpenAccessLink	https://doaj.org/article/d14374e8b806429ea0c1e3a82bbf7661
PMID	29225717
PQID	1975597240
PQPubID	23479
PageCount	11
ParticipantIDs	doaj_primary_oai_doaj_org_article_d14374e8b806429ea0c1e3a82bbf7661 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5715626 proquest_miscellaneous_1975597240 gale_infotracmisc_A517484244 gale_infotracacademiconefile_A517484244 pubmed_primary_29225717 crossref_primary_10_1186_s13148_017_0426_3 crossref_citationtrail_10_1186_s13148_017_0426_3 springer_journals_10_1186_s13148_017_0426_3
PublicationCentury	2000
PublicationDate	2017-12-04
PublicationDateYYYYMMDD	2017-12-04
PublicationDate_xml	– month: 12 year: 2017 text: 2017-12-04 day: 04
PublicationDecade	2010
PublicationPlace	London
PublicationPlace_xml	– name: London – name: Germany
PublicationSubtitle	The official journal of the Clinical Epigenetics Society
PublicationTitle	Clinical epigenetics
PublicationTitleAbbrev	Clin Epigenet
PublicationTitleAlternate	Clin Epigenetics
PublicationYear	2017
Publisher	BioMed Central BioMed Central Ltd BMC
Publisher_xml	– name: BioMed Central – name: BioMed Central Ltd – name: BMC
References	Y Chong (426_CR30) 2014; 31 ZH Huang (426_CR4) 2007; 13 C Ausch (426_CR7) 2009; 55 H Zou (426_CR35) 2006; 15 HM Müller (426_CR40) 2004; 363 426_CR17 426_CR18 F Model (426_CR1) 2007; 5 G Foltz (426_CR32) 2009; 28 MJ Worsham (426_CR31) 2013; 149 426_CR37 T Oh (426_CR20) 2013; 15 K Lenhard (426_CR41) 2005; 3 A Jemal (426_CR2) 2009; 59 DK Rex (426_CR5) 2009; 104 H Fiegel (426_CR12) 2005; 65 E Dejeux (426_CR23) 2007; 9 H Zhang (426_CR9) 2014; 20 TF Imperiale (426_CR19) 2014; 370 SB Baylin (426_CR8) 1998; 72 DA Lieberman (426_CR39) 2000; 343 DR Wang (426_CR14) 2008; 14 PW Laird (426_CR28) 2003; 3 426_CR42 H Ryu (426_CR22) 2009; 284 LS Kristensen (426_CR25) 2008; 36 PA Wayne (426_CR26) 2012; 24 AC Rapraeger (426_CR21) 2000; 149 426_CR29 RE Board (426_CR13) 2008; 2 426_CR24 DH Johnson (426_CR34) 2016; 22 426_CR27 RH Dashwood (426_CR3) 1999; 6 M Widschwendter (426_CR11) 2006; 12 T Kadiyska (426_CR10) 2015; 21 DA Ahlquist (426_CR33) 2000; 31 SC Glöckner (426_CR15) 2009; 69 WD Chen (426_CR16) 2005; 97 D Whitney (426_CR36) 2004; 6 T Morikawa (426_CR6) 2005; 129 A Loktionov (426_CR38) 1998; 4
References_xml	– volume: 20 start-page: 6329 issue: 20 year: 2014 ident: 426_CR9 publication-title: World J Gastroenterol doi: 10.3748/wjg.v20.i20.6329 – ident: 426_CR27 doi: 10.3389/fpubh.2014.00210 – volume: 15 start-page: 1115 issue: 6 year: 2006 ident: 426_CR35 publication-title: Cancer Epidemiol Biomark Prev doi: 10.1158/1055-9965.EPI-05-0992 – volume: 3 start-page: 142 issue: 2 year: 2005 ident: 426_CR41 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/S1542-3565(04)00624-X – volume: 149 start-page: 995 year: 2000 ident: 426_CR21 publication-title: J Cell Biol doi: 10.1083/jcb.149.5.995 – volume: 15 start-page: 498 issue: 4 year: 2013 ident: 426_CR20 publication-title: J Mol Diagn. doi: 10.1016/j.jmoldx.2013.03.004 – volume: 24 start-page: EP17 issue: 34 year: 2012 ident: 426_CR26 publication-title: CLSI document – volume: 12 start-page: 7205 year: 2006 ident: 426_CR11 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-2531 – volume: 284 start-page: 35692 year: 2009 ident: 426_CR22 publication-title: J Biol Chem doi: 10.1074/jbc.M109.054254 – volume: 2 start-page: 307 year: 2008 ident: 426_CR13 publication-title: Biomark Insights – volume: 5 start-page: 153 issue: 2 year: 2007 ident: 426_CR1 publication-title: Mol Cancer Res doi: 10.1158/1541-7786.MCR-06-0034 – volume: 6 start-page: 277 year: 1999 ident: 426_CR3 publication-title: Oncol Rep – ident: 426_CR17 doi: 10.1053/j.gastro.2011.10.031 – ident: 426_CR24 doi: 10.1186/1471-2199-8-91 – volume: 55 start-page: 1559 issue: 8 year: 2009 ident: 426_CR7 publication-title: Clin Chem doi: 10.1373/clinchem.2008.122937 – volume: 22 start-page: 1559 issue: 7 year: 2016 ident: 426_CR34 publication-title: Inflamm Bowel Dis doi: 10.1097/MIB.0000000000000795 – volume: 36 start-page: e42 issue: 7 year: 2008 ident: 426_CR25 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkn113 – volume: 363 start-page: 1283 issue: 9417 year: 2004 ident: 426_CR40 publication-title: Lancet doi: 10.1016/S0140-6736(04)16002-9 – volume: 69 start-page: 4691 issue: 11 year: 2009 ident: 426_CR15 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-08-0142 – volume: 28 start-page: 2667 issue: 29 year: 2009 ident: 426_CR32 publication-title: Oncogene doi: 10.1038/onc.2009.122 – volume: 149 start-page: 409 issue: 3 year: 2013 ident: 426_CR31 publication-title: Otolaryngol Head Neck Surg doi: 10.1177/0194599813490895 – ident: 426_CR42 doi: 10.3390/genes7120125 – volume: 4 start-page: 337 issue: 2 year: 1998 ident: 426_CR38 publication-title: Clin Cancer Res – volume: 6 start-page: 386 issue: 4 year: 2004 ident: 426_CR36 publication-title: J Mol Diag doi: 10.1016/S1525-1578(10)60536-3 – volume: 31 start-page: 2535 issue: 6 year: 2014 ident: 426_CR30 publication-title: Oncol Rep doi: 10.3892/or.2014.3149 – volume: 343 start-page: 162 issue: 3 year: 2000 ident: 426_CR39 publication-title: N Eng J Med doi: 10.1056/NEJM200007203430301 – ident: 426_CR18 doi: 10.1158/1055-9965 – ident: 426_CR29 – volume: 59 start-page: 225 issue: 4 year: 2009 ident: 426_CR2 publication-title: CA Cancer J Clin doi: 10.3322/caac.20006 – volume: 97 start-page: 1124 issue: 15 year: 2005 ident: 426_CR16 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/dji204 – volume: 31 start-page: 51 issue: 1 year: 2000 ident: 426_CR33 publication-title: Hum Pathol doi: 10.1016/S0046-8177(00)80198-7 – volume: 21 start-page: 10057 issue: 35 year: 2015 ident: 426_CR10 publication-title: World J Gastroenterol doi: 10.3748/wjg.v21.i35.10057 – volume: 104 start-page: 739 year: 2009 ident: 426_CR5 publication-title: Am J Gastroenterol doi: 10.1038/ajg.2009.104 – volume: 370 start-page: 1287 issue: 14 year: 2014 ident: 426_CR19 publication-title: N Eng J Med. doi: 10.1056/NEJMoa1311194 – volume: 9 start-page: 510 issue: 4 year: 2007 ident: 426_CR23 publication-title: J Mol Diagn doi: 10.2353/jmoldx.2007.060209 – volume: 129 start-page: 422 issue: 2 year: 2005 ident: 426_CR6 publication-title: Gastroenterol doi: 10.1016/j.gastro.2005.05.056 – volume: 65 start-page: 1141 year: 2005 ident: 426_CR12 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-04-2438 – volume: 3 start-page: 253 issue: 4 year: 2003 ident: 426_CR28 publication-title: Nat Rev Cancer doi: 10.1038/nrc1045 – volume: 72 start-page: 141 year: 1998 ident: 426_CR8 publication-title: Adv Cancer Res doi: 10.1016/S0065-230X(08)60702-2 – ident: 426_CR37 doi: 10.1186/s12896-015-0148-6 – volume: 14 start-page: 524 issue: 4 year: 2008 ident: 426_CR14 publication-title: World J Gastroenterol doi: 10.3748/wjg.14.524 – volume: 13 start-page: 950 issue: 6 year: 2007 ident: 426_CR4 publication-title: World J Gastroenterol doi: 10.3748/wjg.v13.i6.950
SSID	ssj0000399910
Score	2.431671
Snippet	Background Colorectal cancer (CRC) screening is the most efficient strategy to reduce disease-related mortality. Frequent aberrant DNA methylation is known to... Colorectal cancer (CRC) screening is the most efficient strategy to reduce disease-related mortality. Frequent aberrant DNA methylation is known to occur in... Background Colorectal cancer (CRC) screening is the most efficient strategy to reduce disease-related mortality. Frequent aberrant DNA methylation is known to... Abstract Background Colorectal cancer (CRC) screening is the most efficient strategy to reduce disease-related mortality. Frequent aberrant DNA methylation is...
SourceID	doaj pubmedcentral proquest gale pubmed crossref springer
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	126
SubjectTerms	Adult Aged Analysis Biomarkers, Tumor - genetics Biomedical and Life Sciences Biomedicine Cancer epigenetics and diagnostics Cancer screening Colorectal cancer Colorectal Neoplasms - diagnosis Colorectal Neoplasms - genetics CpG Islands Development and progression DNA Methylation Early detection Epigenesis, Genetic Feasibility Studies Feces - chemistry Female Gene Function HCT116 Cells Health aspects HT29 Cells Human Genetics Humans Male Methylation Middle Aged Mortality Precancerous lesion SDC2 Sensitivity and Specificity Sequence Analysis, DNA Stool DNA Syndecan-2 - genetics
SummonAdditionalLinks	– databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5BAYlLeRYCBRkJCQkUkcRZxzkuLRWnFaKAKi6Wn3SlKoHNLlL_fWecZEXKQ4Lr2snazjy-sWc-AzznBEOs8xim1iEthc3S2paoV9LJivh8eaHjZRPVYiFPTur3Qx13N2a7j0eS0VJHtZbidZdz2vwiq0q4P-VX4Rp6O0na-OH483ZjJeOEeWIhpBQyrdAnDqeZv33LxB9F2v5fjfNP3uly5uSl49PolY5u_dd8bsPuAELZvJeaO3DFN3fhxpc2brHfA424cMiaPWdtYN83mlKKqCCKHR8eFIyunT7vk-jYsmGIH9szdriYM0TAzBNlMnN-HZO8GnoBMWOTZcX_tCRlq_vw6ejtx4N36XAVQ2pFma_TmTU-M5XGEYvSCM9rPUPn54SXXgQnZq50UmQ65DbPtHChDMFlxmkhnZfS8D3YadrGPwQWTM6ddAgEKcdU6xohVm1Kora3NudVAtn4QZQdeMrpuowzFeMVKVS_cgpXTtHKKZ7Ay-0j33qSjr91fkNfeduR-LXjD-3qqxrUVTmEkVXppZEUoNVeZzb3XMvCmFAhpEngBcmIIiuAg7N6KGbAKRKflpoTAbikIsIE9ic9UXvtpPnZKGWKmijlrfHtplN5XVG0h4grgQe91G3HXNRohjEQT6CayONkUtOWZnkaycPxMYS8IoFXo1SqwWp1f16zR__U-zHcLEisKemn3Ied9Wrjn8B1-2O97FZPo7ZeACANN7g priority: 102 providerName: Springer Nature
Title	Feasibility of quantifying SDC2 methylation in stool DNA for early detection of colorectal cancer
URI	https://link.springer.com/article/10.1186/s13148-017-0426-3 https://www.ncbi.nlm.nih.gov/pubmed/29225717 https://www.proquest.com/docview/1975597240 https://pubmed.ncbi.nlm.nih.gov/PMC5715626 https://doaj.org/article/d14374e8b806429ea0c1e3a82bbf7661
Volume	9
WOSCitedRecordID	wos000416971800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVADU databaseName: BioMed Central Open Access Free customDbUrl: eissn: 1868-7083 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000399910 issn: 1868-7075 databaseCode: RBZ dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1868-7083 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000399910 issn: 1868-7075 databaseCode: DOA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1868-7083 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000399910 issn: 1868-7075 databaseCode: M7P dateStart: 20150101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1868-7083 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000399910 issn: 1868-7075 databaseCode: 7X7 dateStart: 20150101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1868-7083 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000399910 issn: 1868-7075 databaseCode: BENPR dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Publicly Available Content Database customDbUrl: eissn: 1868-7083 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000399910 issn: 1868-7075 databaseCode: PIMPY dateStart: 20150101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1868-7083 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000399910 issn: 1868-7075 databaseCode: RSV dateStart: 20100901 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bi9QwFD7oquCLeF2r6xBBEJSybdNJ0sfZG_rgUHZVRl9CmqQ4sLQ6F2H_veeknWG6or74MtAmnTbJuXynPfkOwCtOMMQ6j2FqUce5sElc2Bz1Sjklic-XZyYUm5DTqZrNinKn1BflhHX0wN3EHTp06DL3qlIElQtvEpt6blRWVbUUXeCDt9sJpoIN5gR8wm5IJVQs0TH2nzTx-HCZcnqPRgaaQoiYD5xS4O7_3ULvuKjr6ZPXvqEG13R2H-71mJJNurE8gBu-eQh3vrbhjfkjMAjz-iTYK9bW7MfaUIYQ7W9iFyfHGaMq0lddThybNwzhYHvJTqYThoCWeWJAZs6vQs5WQ39ARNdkKPGeloRm8Rg-nZ1-PH4X95UVYivydBWPbeWTShqcBZFXwvPCjNGXOeGVF7UTY5c7JRJTpzZNjHB1XtcuqZwRynmlKv4E9pq28U-B1VXKnXKI6yhl1JgCEVNR5cRUb23KZQTJZmq17WnHqfrFpQ7hhxK6Ww2Nq6FpNTSP4M32ku8d58bfOh_Rem07El12OIFCpHsh0v8Soghe02prUmp8OGv6vQk4RKLH0hPi81a0JzCCg0FPVEY7aH65kRdNTZTB1vh2vdRpISl4QwAVwX4nP9tnzgq0qhhXRyAHkjUY1LClmX8LXOB4GSJYEcHbjQzq3ggt_zxnz_7HnD2HuxlpEKX25Aewt1qs_Qu4bX-u5svFCG7KmQy_agS3jk6n5fkoqOiIsmtLPFe-_1B-waPzi8-_AEv9Owc
linkProvider	Directory of Open Access Journals
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwEB5BAZUX7iNQwEhISKCIJPY6zuPSUhVRVogWVPXFcmynrFQlsNlF6r9nxklWpBwSvK6drO3M8Y098xngGScYYp3HMLWoYiFtEhdWoF4pp3Li8-WZCZdN5LOZOjoqPvR13O2Q7T4cSQZLHdRayVdtymnzi6wq4f6YX4RLAh0W5fF9PPi83lhJOGGeUAippIpz9In9aeZv3zLyR4G2_1fj_JN3Op85ee74NHil3ev_NZ8bcK0HoWzaSc1NuODrW3DluAlb7LfBIC7ss2bPWFOxbytDKUVUEMUOdrYzRtdOn3VJdGxeM8SPzSnbmU0ZImDmiTKZOb8MSV41vYCYscmy4n9akrLFHfi0--Zwey_ur2KIrRTpMp7Y0idlbnDEUpTS88JM0Pk56ZWXlZMTJ5ySialSmyZGukpUlUtKZ6RyXqmS34WNuqn9fWBVmXKnHAJByjE1pkCIVZSCqO2tTXkeQTJ8EG17nnK6LuNUh3hFSd2tnMaV07RymkfwYv3I146k42-dX9NXXnckfu3wQ7M40b26aocwMhdelYoCtMKbxKaeG5WVZZUjpIngOcmIJiuAg7OmL2bAKRKflp4SAbiiIsIItkY9UXvtqPnpIGWamijlrfbNqtVpkVO0h4grgnud1K3HnBVohjEQjyAfyeNoUuOWev4lkIfjYwh5ZQQvB6nUvdVq_7xmD_6p9xPY3Dt8v6_3387ePYSrGYk4JQCJLdhYLlb-EVy235fzdvE4aO4PvmA6nA
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3ri9QwEB_0fOAX34_qqREEwaNc22TT9ON666Ioy8GpHH4JeVUXjvbcdoX7751pu4s9HyB-3aTdJJ2Z_CaZ-Q3Ac04wxPmAbmpRxkK6JC6cQL1SXuXE58sz0xWbyBcLdXxcHA51TptNtPvmSrLPaSCWpqrdP_Vlr-JK7jcpp4MwsrDkA8T8IlwSVDOI3PWjT9tDloQT_umSIpVUcY7743Cz-du3jPamjsL_V0P90051Pory3FVqt0PNb_z33G7C9QGcsmkvTbfgQqhuw5XPdXf0fgcM4sUhmvaM1SX7tjYUakSJUuxodpAxKkd91gfXsWXFEFfWJ2y2mDJExiwQlTLzoe2Cvyp6ATFmk8XF_3Qkfau78HH--sPBm3go0RA7KdI2njgbEpsbHLEUVgZemAluil4GFWTp5cQLr2RiytSliZG-FGXpE-uNVD4oZfk92KnqKjwAVtqUe-URIFLsqTEFQq_CCqK8dy7leQTJ5uNoN_CXUxmNE935MUrqfuU0rpymldM8gpfbR0578o6_dX5FX3zbkXi3ux_q1Rc9qLH2CC9zEZRV5LgVwSQuDdyozNoyR6gTwQuSF03WAQfnzJDkgFMkni09JWJwRcmFEeyOeqJWu1Hzs43EaWqiULgq1OtGp0VOXiAisQju9xK4HXNWoHlGBz2CfCSbo0mNW6rl145UHB9DKCwj2NtIqB6sWfPnNXv4T72fwtXD2Vy_f7t49wiuZSThFBckdmGnXa3DY7jsvrfLZvWkU-Iff-9DgA
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Feasibility+of+quantifying+SDC2+methylation+in+stool+DNA+for+early+detection+of+colorectal+cancer&rft.jtitle=Clinical+epigenetics&rft.au=Oh%2C+Tae+Jeong&rft.au=Oh%2C+Hyun+Il&rft.au=Seo%2C+Yang+Yei&rft.au=Jeong%2C+Dongjun&rft.date=2017-12-04&rft.pub=BioMed+Central&rft.issn=1868-7075&rft.eissn=1868-7083&rft.volume=9&rft_id=info:doi/10.1186%2Fs13148-017-0426-3&rft_id=info%3Apmid%2F29225717&rft.externalDocID=PMC5715626
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1868-7075&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1868-7075&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1868-7075&client=summon